Last reviewed · How we verify
Head And Neck Cancer
Approved treatments
- Erbitux · Imclone
Erbitux works by binding to the Epidermal Growth Factor Receptor (EGFR) on cancer cells, blocking the receptor's ability to stimulate cell growth and division. - Opdivo · Bristol-Myers Squibb
Opdivo works by blocking the PD-1 receptor on immune cells, allowing them to attack cancer cells. - Erbitux · Hellenic Oncology Research Group
Clinical guidelines
- FDA label — 1L
ERBITUX in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN). - FDA label — 1L
ERBITUX in combination with platinum-based therapy with fluorouracil for the first-line treatment of patients with recurrent locoregional disease or metastatic SCCHN. - FDA label — 2L+
ERBITUX as a single-agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape: